UCB.BR
UCB SA
Price history
Key metrics
UCB SA has paid a dividend for 31 consecutive years and currently yields 0.72%, below its five year average. Its payout ratio is 18%. Dividend Health rates it Very safe at 89 out of 99, with high confidence.
Data as of 15 Oct 2026
Next dividend
Per share
€1.45
Frequency
Final
Declared
—
Ex-date
26 Apr 2027
in 193 days
Pay date
29 Apr 2027
estimated
Dividend health
Confidence High · Defensive profile · as of 15 Oct 2026
Total return
€10,000 invested is €33,747 today: €20,629 from the share price and €3,118 from dividends reinvested.
Total return +237.47%. Price alone returned +206.29% over the same window.
Assumes every dividend is reinvested on its ex-dividend date, before tax and dealing costs.
How it compares
Where it trades
Same company, 2 securities
Each has its own ISIN. Currency, dividends and tax withholding can differ, and one unit is not always one share.
Volume: median shares per session over the last 20 sessions. Closes as of 14 Oct 2026. Regular trading hours in your time zone.
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Annual dividends per share
Dividends paid in EUR · based on UCB.BR's fiscal years ending in December
Dividend Policy
The Board intends to continue to sustain a dynamic dividend policy, consistent with the long-term growth prospects of the Company, offering gradual increase in dividend, and as far as possible not to reduce it, irrespective of the short-term income variations.
Dividend History
| Ex-Date | Amount | Status |
|---|---|---|
| 26 Apr 272027-04-26 | €1.4500 | Estimated |
| 04 May 262026-05-04 | €1.4500 | Paid |
| 25 Apr 252025-04-25 | €1.3900 | Paid |
| 26 Apr 242024-04-26 | €1.3600 | Paid |
| 28 Apr 232023-04-28 | €1.3300 | Paid |
| 29 Apr 222022-04-29 | €1.3000 | Paid |
| 30 Apr 212021-04-30 | €1.2700 | Paid |
| 04 May 202020-05-04 | €1.2400 | Paid |
| 26 Apr 192019-04-26 | €1.2100 | Paid |
| 27 Apr 182018-04-27 | €1.1800 | Paid |
| 28 Apr 172017-04-28 | €1.1500 | Paid |
| 29 Apr 162016-04-29 | €1.1000 | Paid |
| 04 May 152015-05-04 | €1.0600 | Paid |
| 29 Apr 142014-04-29 | €1.0400 | Paid |
| 02 May 132013-05-02 | €1.0200 | Paid |
| 27 Apr 122012-04-27 | €1.0000 | Paid |
| 02 May 112011-05-02 | €0.9800 | Paid |
| 03 May 102010-05-03 | €0.9600 | Paid |
| 05 May 092009-05-05 | €0.9200 | Paid |
| 28 Apr 082008-04-28 | €0.9200 | Paid |
| 30 Apr 072007-04-30 | €0.9000 | Paid |
| 16 Jun 062006-06-16 | €0.8800 | Paid |
| 17 Jun 052005-06-17 | €0.8600 | Paid |
| 11 Jun 042004-06-11 | €0.8200 | Paid |
| 13 Jun 032003-06-13 | €0.8000 | Paid |
| 14 Jun 022002-06-14 | €0.7600 | Paid |
| 14 Jun 012001-06-14 | €0.6400 | Paid |
| 14 Jun 002000-06-14 | €0.5000 | Paid |
| 11 Jun 991999-06-11 | €0.3800 | Paid |
| 11 Jun 981998-06-11 | €0.2107 | Paid |
| 23 Dec 971997-12-23 | €0.0248 | Paid |
| 25 Jun 971997-06-25 | €0.1611 | Paid |
| 16 Dec 961996-12-16 | €0.0248 | Paid |
| 20 Jun 961996-06-20 | €0.1240 | Paid |
| 15 Dec 951995-12-15 | €0.0248 | Paid |
For information only, not investment advice. Past dividends are no guarantee of future payments. Prices are closing prices from the last trading day.
Your dividend income, mapped.
Free for up to 25 holdings. No credit card. Import your first portfolio in under a minute.
Get started free